Newsletter | May 9, 2025

05.09.25 -- Essential Medicines And The Need For A Robust U.S. Supply Chain

NEW PODCAST EPISODE

Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

Discover how Alnylam is bringing RNAi therapies to broader patient populations. EVP Tolga Tanguler shares insights on reimbursement, value-based contracts, and redefining commercialization in biotech. Listen now to learn how RNAi is scaling beyond rare disease—only on Business of Biotech. Brought to you by Avantor.

FEATURED ARTICLE

Essential Medicines And The Need For A Robust U.S. Supply Chain

Improvements to the U.S. supply chain are needed to reduce shortages and protect American patients. Industry, academia, regulators, and politicians will need to work together, explains Dave Stowe.

INDUSTRY INSIGHTS

Global Trial Disclosure Landscape Grows Increasingly Complex

The industry is witnessing a trend toward increased transparency and more stringent enforcement of clinical trial reporting requirements. Yet mechanisms and penalties differ across regions and countries.

Strategies For A More Secure Outsourcing Bottom Line

A panel of experts from across the pharmaceutical/biopharmaceutical industry recently shared their experiences in mitigating financial risk before partnering with a contract research organization (CRO).

Capitalizing On Biotech Collaboration: A CFO's Guide To Driving Growth

Navigate the evolving biotech landscape and secure venture capital with insights on strategic partnerships and investor expectations.

Improving Therapeutic Protein Efficacy Through Charge Profile Adjustment

By adequately measuring charge variants early in development and implementing effective control strategies, developers can mitigate risks and ensure the safety and efficacy of their mAb products.

SPONSOR

DIA 2025 Global Annual Meeting

In a time of rapid change, no single discipline can move forward alone. DIA 2025 Global Annual Meeting (DIA 2025) brings together regulatory, clinical, safety, and operational leaders to confront shared challenges and design smarter, faster, more connected solutions. From real-time FDA insights to global regulatory and multi-disciplinary collaboration, DIA 2025 is where silos break down and progress accelerates. Join the conversation that’s shaping what’s next!

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.